Time for adjuvant vemurafenib?
نویسندگان
چکیده
منابع مشابه
Delayed-onset vemurafenib-induced panniculitis
INTRODUCTION Approved in 2011, vemurafenib is a selective serine/threonine kinase inhibitor directed against the V600E mutation in the BRAF gene. This drug is often used in dermatology as a targeted therapy for metastatic or unresectable melanomas, for which about 50% have this mutation. Other tumors possessing the V600E mutation are targets for this therapy. The commonly reported adverse effec...
متن کاملVemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma
The BRAF inhibitor, vemurafenib, has demonstrated improved progression-free and overall survival compared with chemotherapy in a randomized trial, and represents a new standard of care in patients with advanced melanoma harboring a BRAF-V600 mutation. A BRAF-V600 mutation is identified in approximately half of patients with cutaneous melanoma, and is unequivocally a biomarker predictive of prof...
متن کاملCombined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
Background BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma. However, median progression-free survival is only 6.9 months in the phase 3 study. Retrospective analyses suggest that treatment with BRAF inhibitors beyond initial progression might be associated with improved overall survival. We aimed to prospect...
متن کاملa time-series analysis of the demand for life insurance in iran
با توجه به تجزیه و تحلیل داده ها ما دریافتیم که سطح درامد و تعداد نمایندگیها باتقاضای بیمه عمر رابطه مستقیم دارند و نرخ بهره و بار تکفل با تقاضای بیمه عمر رابطه عکس دارند
ذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Clinical Oncology
سال: 2018
ISSN: 1759-4774,1759-4782
DOI: 10.1038/nrclinonc.2018.39